

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE AND NOMINATION COMMITTEE

RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Keymed Biosciences Inc. (the “**Company**”) announces that Prof. Linqing LIU (“**Prof. Liu**”) will retire as an independent non-executive Director and will not offer himself for re-election at the forthcoming annual general meeting of the Company which is expected to be held on June 27, 2023 (the “**AGM**”). He will also cease to be a member of the Board’s audit committee (the “**Audit Committee**”) and the Board’s nomination committee (the “**Nomination Committee**”) with effect from the conclusion of the AGM.

Prof. Liu shall retire from his position in order to devote more time to pursue his other business engagements and has confirmed that he has no claim against the Company in respect of his retirement and has no disagreement with the Board. Prof. Liu has further confirmed that there is no matter relating to his retirement that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board would like to express its sincere gratitude to Prof. Liu for his valuable contributions during his tenure of office as an independent non-executive Director.

CHANGE OF COMPOSITION OF AUDIT COMMITTEE AND NOMINATION COMMITTEE

With effect from the conclusion of the AGM, Prof. Yang KE, an independent non-executive Director, will be appointed as a member of the Audit Committee, and Mr. Cheuk Kin Stephen LAW, an independent non-executive Director, will be appointed as a member of the Nomination Committee.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, April 17, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.